|
43 Companies |
|
55 Products |
|
55 Products |
|
60 Mechanisms of Action |
|
1 Trial |
|
670 News |
|
| 12345678910111213...1314» |
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Apr 21, 2019
P2, N=43, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed --> Terminated; Initiation of CMS BMT study for sickle-cell disease operating under NCT01166009 made further accrual to this study impossible.
- | Trial completion: Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C (clinicaltrials.gov) - Apr 10, 2019
P=N/A, N=60, Completed, Sponsor: Tanta University
Completed --> Terminated; Initiation of CMS BMT study for sickle-cell disease operating under NCT01166009 made further accrual to this study impossible. Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Mar 14, 2019
P=N/A, N=62, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Aug 2018 | Trial primary completion date: Jan 2019 --> Aug 2018
- | Trial completion: IMPROVE: Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease (clinicaltrials.gov) - Mar 11, 2019
P2, N=54, Completed, Sponsor: Jeffrey Glassberg
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Aug 2018 | Trial primary completion date: Jan 2019 --> Aug 2018 Recruiting --> Completed
- | deferasirox tablet for oral suspension / Generic mfg., deferiprone / Generic mfg.
Trial completion: Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia (clinicaltrials.gov) - Mar 6, 2019
P1/2, N=9, Completed, Sponsor: Children's Hospital of Philadelphia
Recruiting --> Completed Active, not recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Jan 22, 2019
P2, N=43, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Iron Mediated Vascular Disease in Sickle Cell Anemia Patients (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=150, Completed, Sponsor: Children's Hospital Los Angeles
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Dec 22, 2018
P=N/A, N=62, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Jan 2019
- | Enrollment change, Trial completion date, Trial primary completion date: Bi-Level Positive Airway Ventilation for Acute Chest Syndrome (clinicaltrials.gov) - Dec 12, 2018
P=N/A, N=3, Terminated, Sponsor: Albert Einstein College of Medicine, Inc.
Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Jan 2019 N=60 --> 3 | Trial completion date: Jul 2014 --> Sep 2016 | Trial primary completion date: Jul 2014 --> Sep 2016
- | Trial completion: Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease (clinicaltrials.gov) - Nov 23, 2018
P=N/A, N=91, Completed, Sponsor: Steven J. Hardy
N=60 --> 3 | Trial completion date: Jul 2014 --> Sep 2016 | Trial primary completion date: Jul 2014 --> Sep 2016 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: DREAM²t: Sickle Cell Anemia and Cerebral Microcirculation : Multimodal Exploration (clinicaltrials.gov) - Nov 15, 2018
P=N/A, N=64, Completed, Sponsor: Imagine Institute
Active, not recruiting --> Completed Trial completion date: Jul 2016 --> Jul 2017 | Trial primary completion date: Jul 2016 --> Jul 2017
- | Trial completion date: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders (clinicaltrials.gov) - Oct 16, 2018
P1, N=28, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Jul 2016 --> Jul 2017 | Trial primary completion date: Jul 2016 --> Jul 2017 Trial completion date: Sep 2015 --> Oct 2018
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial (clinicaltrials.gov) - Oct 11, 2018
P4, N=7, Completed, Sponsor: Ala'a Sharara
Trial completion date: Sep 2015 --> Oct 2018 Recruiting --> Completed | N=10 --> 7 | Trial completion date: Sep 2017 --> Aug 2018 | Trial primary completion date: Aug 2017 --> Aug 2018
- | azithromycin / Generic mfg.
Enrollment change, Trial withdrawal: Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease (clinicaltrials.gov) - Oct 2, 2018
P1/2, N=0, Withdrawn, Sponsor: Vanderbilt University
Recruiting --> Completed | N=10 --> 7 | Trial completion date: Sep 2017 --> Aug 2018 | Trial primary completion date: Aug 2017 --> Aug 2018 N=40 --> 0 | Recruiting --> Withdrawn
- | Trial completion date, Trial primary completion date: tDCS/PES_SCD: tDCS Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease (clinicaltrials.gov) - Sep 24, 2018
P2, N=120, Recruiting, Sponsor: Faculdade Adventista da Bahia
N=40 --> 0 | Recruiting --> Withdrawn Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2017 --> Dec 2022
- | Trial completion, Trial completion date: MEMREAD: Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease (clinicaltrials.gov) - Sep 12, 2018
P=N/A, N=84, Completed, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2017 --> Dec 2022 Recruiting --> Completed | Trial completion date: Mar 2019 --> Aug 2018
- | Trial completion: Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major (clinicaltrials.gov) - Sep 11, 2018
P=N/A, N=60, Completed, Sponsor: Tanta University
Recruiting --> Completed | Trial completion date: Mar 2019 --> Aug 2018 Active, not recruiting --> Completed
- | Trial completion: Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C (clinicaltrials.gov) - Sep 11, 2018
P=N/A, N=60, Completed, Sponsor: Tanta University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C (clinicaltrials.gov) - Sep 11, 2018
P=N/A, N=30, Completed, Sponsor: Tanta University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Aug 21, 2018
P2, N=43, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Trial primary completion date: May 2018 --> Dec 2018
- | Trial completion, Trial completion date, Trial primary completion date: CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant (clinicaltrials.gov) - Aug 21, 2018
P2, N=20, Completed, Sponsor: New York Medical College
Trial primary completion date: May 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Nov 2017
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Improving Sickle Cell Disease (SCD) Care Using Web-based Guidelines (clinicaltrials.gov) - Aug 8, 2018
P=N/A, N=213, Completed, Sponsor: Duke University
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Nov 2017 Recruiting --> Completed | N=500 --> 213 | Trial completion date: May 2018 --> Dec 2017 | Trial primary completion date: May 2018 --> Dec 2017
- | Trial completion, Stroma: Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs (clinicaltrials.gov) - Aug 7, 2018
P2, N=6, Completed, Sponsor: Stanford University
Recruiting --> Completed | N=500 --> 213 | Trial completion date: May 2018 --> Dec 2017 | Trial primary completion date: May 2018 --> Dec 2017 Terminated --> Completed
- | Enrollment change, Trial withdrawal: Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) - Aug 2, 2018
P2, N=0, Withdrawn, Sponsor: Wake Forest University Health Sciences
Terminated --> Completed N=24 --> 0 | Suspended --> Withdrawn
- | Trial completion: Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 30, 2018
P1, N=25, Completed, Sponsor: The Cleveland Clinic
N=24 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell (clinicaltrials.gov) - Jul 27, 2018
P=N/A, N=9, Completed, Sponsor: Chattanooga-Hamilton County Hospital Authority
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jan 2017 --> Sep 2016
- | Trial completion: Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion (clinicaltrials.gov) - Jul 19, 2018
P3, N=86, Completed, Sponsor: Cerus Corporation
Recruiting --> Completed | Trial completion date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jan 2017 --> Sep 2016 Active, not recruiting --> Completed
- | NVX-508 / NuvOx Pharma
Enrollment change, Trial withdrawal: A Phase Ib Study of NVX-508 in Sickle Cell Disease (clinicaltrials.gov) - Jul 16, 2018
P1, N=0, Withdrawn, Sponsor: Amma Owusu-Ansah, MD
Active, not recruiting --> Completed N=24 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital. (clinicaltrials.gov) - Jul 12, 2018
P=N/A, N=30, Completed, Sponsor: Brugmann University Hospital
N=24 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
- | Trial completion: Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia (clinicaltrials.gov) - Jul 12, 2018
P=N/A, N=40, Completed, Sponsor: Tanta University
Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018 Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Pain Management in Children and Young Adults With Sickle Cell Disease (clinicaltrials.gov) - Jul 6, 2018
P2, N=90, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=190 --> 90 | Trial completion date: May 2018 --> Jan 2018 | Trial primary completion date: May 2018 --> Jan 2018
- | L-citrulline / Generic mfg.
Enrollment change, Trial withdrawal: A Study of Oral L-citrulline in Sickle Cell Disease (clinicaltrials.gov) - Jun 21, 2018
P1, N=0, Withdrawn, Sponsor: University of Mississippi Medical Center
Recruiting --> Completed | N=190 --> 90 | Trial completion date: May 2018 --> Jan 2018 | Trial primary completion date: May 2018 --> Jan 2018 N=16 --> 0 | Recruiting --> Withdrawn
- | azithromycin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease (clinicaltrials.gov) - Jun 21, 2018
P1, N=0, Withdrawn, Sponsor: University of Mississippi Medical Center
N=16 --> 0 | Recruiting --> Withdrawn N=15 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Dec 2017
- | Trial completion, Trial completion date, Trial primary completion date: Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions (clinicaltrials.gov) - Jun 13, 2018
P4, N=4, Completed, Sponsor: Duke University
N=15 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Dec 2017 Active, not recruiting --> Completed | Trial completion date: May 2018 --> Dec 2017 | Trial primary completion date: May 2018 --> Dec 2017
- ||| tovinontrine (IMR-687) / Imara, Inc
Trial completion, Enrollment change: A Study of IMR-687 in Healthy Adult Volunteers (clinicaltrials.gov) - Jun 3, 2018
P1a, N=66, Completed, Sponsor: Imara, Inc.
Active, not recruiting --> Completed | Trial completion date: May 2018 --> Dec 2017 | Trial primary completion date: May 2018 --> Dec 2017 Recruiting --> Completed | N=36 --> 66
- ||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment change, Trial withdrawal: Safety and Pharmacokinetics of SANGUINATE (clinicaltrials.gov) - Jun 2, 2018
P1, N=0, Withdrawn, Sponsor: Prolong Pharmaceuticals
Recruiting --> Completed | N=36 --> 66 N=15 --> 0 | Suspended --> Withdrawn
- | Trial completion date, Trial primary completion date: Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital. (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=50, Recruiting, Sponsor: Brugmann University Hospital
N=15 --> 0 | Suspended --> Withdrawn Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion, Enrollment change: PHEDRE: Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=1004, Completed, Sponsor: Nantes University Hospital
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Completed | N=2000 --> 1004
- || Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion, Trial completion date: Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis (clinicaltrials.gov) - May 31, 2018
P2, N=24, Completed, Sponsor: Prolong Pharmaceuticals
Not yet recruiting --> Completed | N=2000 --> 1004 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Dec 2017
- || Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion, Trial completion date, Trial primary completion date: A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients (clinicaltrials.gov) - May 30, 2018
P2, N=34, Completed, Sponsor: Prolong Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Dec 2017 Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Dec 2017 --> May 2017
- || EPEG (pegylated recombinant erythropoietin) / Cadila, Prolong Pharma
Trial completion, Trial completion date, Trial primary completion date: A Study of EPEG in Beta Thalassemia Patients (clinicaltrials.gov) - May 29, 2018
P1, N=6, Completed, Sponsor: Prolong Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Dec 2017 --> May 2017 Not yet recruiting --> Completed | Trial completion date: Jun 2017 --> Sep 2017 | Trial primary completion date: May 2017 --> Sep 2017
- | Enrollment change, Trial termination: A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises (clinicaltrials.gov) - May 3, 2018
P=N/A, N=3, Terminated, Sponsor: Valley Anesthesiology Consultants
Not yet recruiting --> Completed | Trial completion date: Jun 2017 --> Sep 2017 | Trial primary completion date: May 2017 --> Sep 2017 N=20 --> 3 | Recruiting --> Terminated; Standard of care changed
- | Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients (clinicaltrials.gov) - Apr 18, 2018
P2, N=30, Active, not recruiting, Sponsor: Prolong Pharmaceuticals
N=20 --> 3 | Recruiting --> Terminated; Standard of care changed Recruiting --> Active, not recruiting | Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Jul 2017 --> Dec 2017
- | Trial completion date, Trial primary completion date: CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant (clinicaltrials.gov) - Apr 9, 2018
P2, N=20, Active, not recruiting, Sponsor: New York Medical College
Recruiting --> Active, not recruiting | Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Jul 2017 --> Dec 2017 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- | montelukast / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) - Apr 3, 2018
P2, N=46, Completed, Sponsor: Vanderbilt University Medical Center
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Mar 2018 | Trial primary completion date: Oct 2018 --> Mar 2018
- | Enrollment closed, Trial completion date, Trial primary completion date: Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions (clinicaltrials.gov) - Mar 30, 2018
P4, N=4, Active, not recruiting, Sponsor: Duke University
Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Mar 2018 | Trial primary completion date: Oct 2018 --> Mar 2018 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: Dec 2017 --> May 2018
- | montelukast / Generic mfg.
Enrollment closed: Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) - Mar 26, 2018
P2, N=63, Active, not recruiting, Sponsor: Vanderbilt University Medical Center
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: Dec 2017 --> May 2018 Recruiting --> Active, not recruiting
- | Phase classification: Lucky Iron Fish Home Fortification of Iron (clinicaltrials.gov) - Mar 16, 2018
P=N/A, N=340, Completed, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Phase classification: P1 --> P=N/A
- NVX-508 / NuvOx Pharma
Trial primary completion date: A Phase Ib Study of NVX-508 in Sickle Cell Disease (clinicaltrials.gov) - Mar 13, 2018
P1, N=24, Not yet recruiting, Sponsor: Amma Owusu-Ansah, MD
Phase classification: P1 --> P=N/A Trial primary completion date: Aug 2018 --> Dec 2018
- | Enrollment closed, Enrollment change: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=62, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Aug 2018 --> Dec 2018 Recruiting --> Active, not recruiting | N=120 --> 62